Decreased oral bioavailability of loxoprofen at second administration in human subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 1, 2000, Pages 10-14

  Kim, I W ^a   Choo, K S ^a   Han, T G ^a   Kim, K S ^b   Chung, S J ^a   Lee, M H ^a   Shim, C K ^a  

^a Seoul National University   (South Korea)

^b Soon Hwa Hospital   (South Korea)

Author keywords

Bioequivalence; Loxoprofen; Period effect

Indexed keywords

LOXIPEN; LOXOPROFEN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; MALE; NORMAL HUMAN;

EID: 0033978872     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38010     Document Type: Article

References (8)

1. English NT, Rankin LC 1997 Antioxidant-mediated attenuation of the induction of cytochrome P450BM-3(CYP102) by ibuprofen in Bacillus megaterium ATCC 14581. Biochem Pharmacol 54: 443-450
2. Kim IW, Han TG, Kim KS, Chung SJ, Lee MH, Shim CK 1998 Bioequivalence of Loxipen tablet to Loxonin tablet in human subjects. J Kor Pharm Sci 28: 185-191
3. Korean Guidelines for Bioequivalence Test 1998. National Institute of Safety Research, Korea
4. Lee YJ, Choi JH, Song SH, Seo CH, Kim DS, Park IS, Choi KH, Na HK, Chung SJ, Lee MH, Shim CK 1998 Development of K-Betest, a computer program for the analysis of bioequivalence. J Kor Pharm Sci 28: 223-229
5. Naganuma H, Kawahara Y 1990 High-performance liquid chromatographic determination of loxoprofen and its diastereomeric alcohol metabolites in biological fluids by fluorescence labelling with 4-bromomethyl-6,7-methylenedioxycoumarin. J Chromatogr 530: 387-396
6. Naruto S, Tanaka Y, Hayashi R, Terada A 1984 Structural determination of rat urinary metabolites of sodium 2-[4-(2-oxocyclopentyl)phenyl]propionate dihydrate (loxoprofen sodium) a new anti-inflammatory agent. Chem Pharm Bull 32: 258-267
7. Shah VP, Midha KK, Dighe S, McGilveray U, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S 1992 Analytic methods validation: bioavailability, bioequivalance and pharmacokinetic studies. Pharm Res 9: 588-592
8. Tanaka Y, Nishikawa Y, Kanno S, Matsyda K, yamazaki M, Terada A, Hayashi R 1983 CS-600, a new anti-inflammatory agent III. Stereospecific formation of an active metabolite. Jpn J Inflammation 3: 151-155